 (Investrend
Research Syndicate) MIV Therapeutics (OTCBB: MIVT) Recent tests have
sown MIV Therapeutics’ (OTCBB: MIVT) biocompatible polymer-free
drug-eluting stent coating technologies shown to be Better Than the
Industry’s Benchmark Cypher Stent.
(Investrend Research
Syndicate) Recent tests have sown MIV Therapeutics’ (OTCBB: MIVT)
biocompatible polymer-free drug-eluting stent coating technologies
shown to be Better Than the Industry’s Benchmark Cypher Stent,
which is one of the world's best selling drug-eluting stents,
according to Investrend Affiliate SISM Resarch analyst Ernest C.
Schlotter.
The full Research Note, including important disclosures and disclaimers, is available at http://www.sism.com and http://www.investrendresearch.com. In it, analyst Schlotter said:
“Just
last Wednesday, MIVT announced remarkable results from preclinical
studies of two of its novel biocompatible polymer-free drug-eluting
stent coating technologies that matched or even outperformed Cordis’
and Boston Scientific’s drug eluting stents. The independently
conducted four-week porcine study at the Erasmus University Medical
Center in the Netherlands compared stents coated with MIVT's
polymer-free drug-eluting technologies to the industry's benchmark, the
J&J Cypher stent, one of the world's best selling drug-eluting
stents. Three variations of MIVT's polymer-free Sirolimus eluting
coatings were at least as effective as -- and in some cases, better --
than Johnson & Johnson's Cypher drug-eluting cardiovascular stents.
Based on these results, MIVT will begin preparations for human
implantation.
“MIV Therapeutics is developing a diverse suite of polymer-free HAp coating formulas…
“The
drug-eluting stent market grew from zero to $5.3 billion in three years
and has captured 85% of the US stent market. To date, more than nine
million DES devices have been inserted. In 2005, about 1.5 million
patients were implanted with drug-eluting stents in the US alone...
“Despite
a stock price increase of more than 50% since last Wednesday, in our
view, MIVT, at a market cap of only $35 million, is still massively
undervalued...
MIV Therapeutics is paying SISM Research $2,250 per month over a two-year period solely to ensure independent coverage. “
SISM
Research, based in Zurich, Switzerland, is a private investment
research firm offering high-quality, independent, fundamental research
on public companies since 1995. SISM writes, publishes and distributes
research coverage, in both English and German, on micro- to small-cap
public companies trading on the OTC, NASDAQ and AMEX.
This
coverage is geared toward institutional and individual investors in
both North America and in German-speaking Europe, a market that
represents more than 100 million people. SISM Research is a content
provider to Thomson Financials OneAnalytics/FirstCall and Investext, to
Reuters Multex, and Investrend.
The full report, including important disclosures and disclaimers, is available at http://www.sism.com, http://www.investrendresearch.com, and at the company’s InvestorPower Page accessible from http://www.investrend.com/company/list.asp?sPathParam=yes. Investors are advised to read those disclosures carefully before trading in the equities of any enrolled company.
Both SISM Research and Investrend Research subscribe to the “Standards for Independent Research Providers” at http://www.firstresearchconsortium.com, and MIVT’s research will be enrolled for investor monitoring by the not-for-profit Shareholders Research Alliance, Inc. (http://www.shareholdersresearch.com).
Anyone
interested in receiving alerts regarding MIV Therapeutics research
should email contact@investrend.com with "MIVT" in the subject
line.
[PLEASE CLICK ON 'ATTACHED REPORT' ABOVE FOR COMPLETE REPORT, INCLUDING IMPORTANT DISCLOSURES AND DISCLAIMERS]
Go to MIV Therapeutics InvestorPower Page
Go to SISM Research
PRINT THIS PAGE | SEND IT TO A FRIEND | | | |
|
|